AbbVie signs HUMIRA global patent license with Pfizer.
M2 PHARMA-December 3, 2018-AbbVie signs HUMIRA global patent license with Pfizer
(C)2018 M2 COMMUNICATIONS
Biopharmaceutical company AbbVie (NYSE:ABBV) revealed on Friday that it has entered into patent license agreements with Pfizer over its proposed biosimilar adalimumab product.
In conjunction with the agreements, AbbVie will provide Pfizer with a non-exclusive license on specified dates to AbbVie's intellectual property relating to HUMIRA in the US and in various other countries around the world in which AbbVie has intellectual property:
In the US, Pfizer's license will begin on 20 November 2023 and will not be accelerated by the entry of companies who have already taken a license.
Additionally, Pfizer can launch the product in the EU upon approval from the European Medicines Agency (EMA).
Pursuant to the agreements, Pfizer will pay royalties to AbbVie for licensing its HUMIRA patents and acknowledges the validity of the licensed patents. AbbVie will make no payments to Pfizer.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 3, 2018|
|Previous Article:||US FDA clears the first Alethia CMV Assay Test System in detecting cytomegalovirus herpes virus in newborns.|
|Next Article:||H. Lundbeck and Otsuka report positive clinical phase II data for the combination treatment of brexpiprazole and sertraline for treatment of PTSD.|